Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 294143, 11 pages
http://dx.doi.org/10.1155/2014/294143
Research Article

Caspase Mediated Synergistic Effect of Boswellia serrata Extract in Combination with Doxorubicin against Human Hepatocellular Carcinoma

1Department of Pharmacology, Faculty of Pharmacy, Hamdard University, Hamdard Nagar, New Delhi 110062, India
2Department of Pharmacognosy & Phytochemistry, Faculty of Pharmacy, Hamdard University (Jamia Hamdard), Hamdard Nagar, New Delhi 110062, India

Received 27 February 2014; Revised 20 June 2014; Accepted 23 June 2014; Published 7 August 2014

Academic Editor: Javeed Iqbal

Copyright © 2014 Mohammad Ahmed Khan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Farazi and R. A. DePinho, “Hepatocellular carcinoma pathogenesis: from genes to environment,” Nature Reviews Cancer, vol. 6, no. 9, pp. 674–687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Hossain, D. H. Kim, J. Y. Jang et al., “Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo,” International Journal of Oncology, vol. 40, no. 5, pp. 1636–1642, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. A. K. Nowak, P. K. H. Chow, and M. Findlay, “Systemic therapy for advanced hepatocellular carcinoma: a review,” European Journal of Cancer, vol. 40, no. 10, pp. 1474–1484, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. O. Dudeck and J. Ricke, “Advances in regional chemotherapy of the liver,” Expert Opinion on Drug Delivery, vol. 8, no. 8, pp. 1057–1069, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. H. Silber, G. Barber, L. Paz-Ares, N. Dobbs, and C. Twelves, “Doxorubicin-induced cardiotoxicity,” The New England Journal of Medicine, vol. 333, no. 20, pp. 1359–1360, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. P. D. King and M. C. Perry, “Hepatotoxicity of chemotherapy,” Oncologist, vol. 6, no. 2, pp. 162–176, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. R. S. Benjamin, P. H. Wiernik, and N. R. Bachur, “Adriamycin chemotherapy: efficacy, safety, and pharmacologic basis of an intermittent single high dosage schedule,” Cancer, vol. 33, no. 1, pp. 19–27, 1974. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Wang, E. A. Konorev, S. Kotamraju, J. Joseph, S. Kalivendi, and B. Kalyanaraman, “Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: intermediacy of H2O2-and p53-dependent pathways,” Journal of Biological Chemistry, vol. 279, no. 24, pp. 25535–25543, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Hovorka, V. Subr, D. Větvička et al., “Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 76, pp. 514–524, 2010. View at Publisher · View at Google Scholar
  10. P. Mukhopadhyay, M. Rajesh, S. Bátkai et al., “Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 296, pp. 1466–1483, 2009. View at Google Scholar
  11. Y. Shen, M. Takahashi, H. Byun et al., “Boswellic acid induces epigenetic alterations by modulating DNA methylation in colorectal cancer cells,” Cancer Biology and Therapy, vol. 13, no. 7, pp. 542–552, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. P. Yong, J. H. Lee, J. Bondar, J. A. Harwalkar, H. Safayhi, and M. Golubic, “Cytotoxic action of acetyl-11-keto-β-boswellic acid (AKBA) on meningioma cells,” Planta Medica, vol. 68, no. 5, pp. 397–401, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Shao, C. Ho, C. Chin, V. Badmaev, W. Ma, and M. Huang, “Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture,” Planta Medica, vol. 64, no. 4, pp. 328–331, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Zhao, M. G. Wientjes, and J. L.-. Au, “Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses,” Clinical Cancer Research, vol. 10, no. 23, pp. 7994–8004, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. J. Liu, Å. Nilsson, S. Oredsson, V. Badmaev, W. Z. Zhao, and R. D. Duan, “Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells,” Carcinogenesis, vol. 23, no. 12, pp. 2087–2093, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Pang, Z. Yi, X. Zhang et al., “Acetyl-11-keto-β-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis,” Cancer Research, vol. 69, no. 14, pp. 5893–5900, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Bhushan, A. Kumar, F. Malik et al., “A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells,” Apoptosis, vol. 12, no. 10, pp. 1911–1926, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Kirk, “Targeted therapies: the maths behind combination therapy,” Nature Reviews Clinical Oncology, vol. 10, no. 9, p. 488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Yeo, T. S. Mok, B. Zee et al., “A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma,” Journal of the National Cancer Institute, vol. 97, no. 20, pp. 1532–1538, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Forner, J. M. Llovet, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 379, no. 9822, pp. 1245–1255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Iqbal, K. Dubey, T. Anwer, A. Ashish, and K. K. Pillai, “Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats,” Pharmacological Reports, vol. 60, no. 3, pp. 382–390, 2008. View at Google Scholar · View at Scopus
  22. M. Khan, T. Li, M. K. Ahmad Khan et al., “Alantolactone induces apoptosis in HepG2 cells through GSH depletion, inhibition of STAT3 activation, and mitochondrial dysfunction,” BioMed Research International, vol. 2013, Article ID 719858, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. N. L. Komarova and C. R. Boland, “Cancer: calculated treatment,” Nature, vol. 499, no. 7458, pp. 291–292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Yang, X. Yan, W. Duan et al., “Pterostilbene exerts antitumor activity via the Notch1 signaling pathway in human lung adenocarcinoma cells,” PLoS ONE, vol. 8, no. 5, Article ID e62652, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Liu, L. Wang, Y. Wu et al., “Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway,” Toxicology, vol. 304, pp. 120–131, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Sharma, S. D. Saini, L. B. Kuhn et al., “Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists,” Digestive Diseases and Sciences, vol. 56, no. 2, pp. 569–577, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. R. F. Hoernlein, T. Orlikowsky, C. Zehrer et al., “Acetyl-11-keto-β-boswellic acid induces apoptosis in HL-60 and CCRF- CEM cells and inhibits topoisomerase I,” Journal of Pharmacology and Experimental Therapeutics, vol. 288, no. 2, pp. 613–619, 1999. View at Google Scholar · View at Scopus
  28. M. Lu, L. Xia, H. Hua, and Y. Jing, “Acetyl-keto-β-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells,” Cancer Research, vol. 68, no. 4, pp. 1180–1186, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Zhao, M. G. Wientjes, and J. L. Au, “Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses,” Clinical Cancer Research, vol. 10, no. 23, pp. 7994–8004, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. P. D. Ottewell, H. Mönkkönen, M. Jones, D. V. Lefley, R. E. Coleman, and I. Holen, “Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer,” Journal of the National Cancer Institute, vol. 100, no. 16, pp. 1167–1178, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Xia, D. Chen, R. Han, Q. Fang, S. Waxman, and Y. Jing, “Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells,” Molecular Cancer Therapeutics, vol. 4, no. 3, pp. 381–388, 2005. View at Google Scholar · View at Scopus
  32. T. Syrovets, B. Büchele, C. Krauss, Y. Laumonnier, and T. Simmet, “Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinases,” Journal of Immunology, vol. 174, no. 1, pp. 498–506, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Utaisincharoen, N. Tangthawornchaikul, S. Ubol, P. Chaisuriya, and S. Sirisinha, “Tnf-α induces caspase 3 (CPP 32) dependent apoptosis in human cholangiocarcinoma cell line,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 31, no. 1, pp. 167–170, 2000. View at Google Scholar · View at Scopus
  34. R. M. Locksley, N. Killeen, and M. J. Lenardo, “The TNF and TNF receptor superfamilies: Integrating mammalian biology,” Cell, vol. 104, no. 4, pp. 487–501, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. B. B. Aggarwal, “Signalling pathways of the TNF superfamily: a double-edged sword,” Nature Reviews Immunology, vol. 3, no. 9, pp. 745–756, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. U. Gaur and B. B. Aggarwal, “Regulation of proliferation, survival and apoptosis by members of the TNF superfamily,” Biochemical Pharmacology, vol. 66, no. 8, pp. 1403–1408, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Zamorano, A. L. Mora, M. Boothby, and A. D. Keegan, “NF-kappaB activation plays an important role in the IL-4-induced protection from apoptosis,” International Immunology, vol. 13, no. 12, pp. 1479–1487, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Takada, H. Ichikawa, V. Badmaev, and B. B. Aggarwal, “Acetyl-11-keto-β-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-κB and NF-κB-regulated gene expression,” The Journal of Immunology, vol. 176, no. 5, pp. 3127–3140, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Sferra, A. Vetuschi, V. Catitti et al., “Boswellia serrata and Salvia miltiorrhiza extracts reduce DMN-induced hepatic fibrosis in mice by TGF-beta1 downregulation,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 11, pp. 1484–1498, 2012. View at Google Scholar · View at Scopus
  40. F. Tulubas, A. Gurel, M. Oran, B. Topcu, V. Caglar, and E. Uygur, “The protective effects of ω-3 fatty acids on doxorubicin-induced hepatotoxicity and nephrotoxicity in rats,” Toxicology and Industrial Health. In press.
  41. C. Carvalho, R. X. Santos, S. Cardoso et al., “Doxorubicin: the good, the bad and the ugly effect,” Current Medicinal Chemistry, vol. 16, no. 25, pp. 3267–3285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Kalender, M. Yel, and S. Kalender, “Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats: the effects of vitamin E and catechin,” Toxicology, vol. 209, no. 1, pp. 39–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Kaplan, E. A. Mutlu, M. Benson, J. Z. Fields, A. Banan, and A. Keshavarzian, “Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders,” Complementary Therapies in Medicine, vol. 15, no. 3, pp. 207–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. E. N. Ali and S. Z. Mansour, “Boswellic acids extract attenuates pulmonary fibrosis induced by bleomycin and oxidative stress from gamma irradiation in rats,” Chinese Medicine, vol. 6, article 36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. R. M. Hartmann, M. I. M. Martins, J. Tieppo, H. S. Fillmann, and N. P. Marroni, “Effect of Boswellia serrata on antioxidant status in an experimental model of colitis rats induced by acetic acid,” Digestive Diseases and Sciences, vol. 57, no. 8, pp. 2038–2044, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. S. R. Dalton, S. M. L. Lee, R. N. King et al., “Carbon tetrachloride-induced liver damage in asialoglycoprotein receptor-deficient mice,” Biochemical Pharmacology, vol. 77, no. 7, pp. 1283–1290, 2009. View at Publisher · View at Google Scholar · View at Scopus